EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer

Ji Won Woo, Eun Kyung Han, Koung Jin Suh, Se Hyun Kim, Jee Hyun Kim, So Yeon Park

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07359-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Ji Won Woo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 Beon-gil, Bundang…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, B7-H1 Antigen, Neoadjuvant Therapy, Tumor Microenvironment. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University Bundang Hospital, Roche Diagnostics Korea, Seoul National University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The tumor immune microenvironment can change after neoadjuvant chemotherapy (NAC) for triple-negative breast cancer (TNBC). We aimed to investigate the effects of NAC on PD-L1 (SP142) status and its clinical significance in TNBC.

Methods

Paired samples of biopsy and resection specimens were collected from 182 patients with TNBC before and after NAC. PD-L1 (SP142) expression in immune cells in pre- and post-NAC breast cancer samples and the changes between them were analyzed, along with their relationships with the clinicopathological features and clinical outcomes of the patients.

Results

Of the 182 patients, 61 (33.5%) achieved pathologic complete response (pCR) after NAC. PD-L1 (SP142) positivity, defined as immune cell staining in ≥ 1% of tumor area, was a predictor for pCR. PD-L1-positive immune cells significantly increased after NAC (2.8% to 5.2% on average) in 109 patients with measurable residual disease. Alteration of PD-L1 status was observed in 24 (22.0%) of the 109 patients with measurable residual tumors after NAC, and all PD-L1 status-converted patients, except one, revealed negative-to-positive conversion. Regarding chemotherapeutic agents, the use of platinum agents was associated with a significant increase in PD-L1-positive immune cells after NAC. In survival analyses, a positive PD-L1 status after NAC and increase of PD-L1-positive immune cells after NAC were associated with better recurrence-free survival of the patients.

Conclusion

PD-L1 (SP142) status changes after NAC, mostly as a positive conversion. As PD-L1 (SP142) status can convey prognostic and predictive information, it needs to be tested before and after NAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsB7-H1 AntigenNeoadjuvant TherapyTumor MicroenvironmentHumansFemaleMiddle AgedAdultAgedBiomarkers, TumorPrognosisAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeChemotherapy, AdjuvantNeoplasm StagingClinical Relevance

Stichwörter der Autor:innen

Neoadjuvant chemotherapyPD-L1SP142Triple-negative breast cancer

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam, Gyeonggi, 13620, Republic of Korea.
  • Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Gyeonggi, Republic of Korea.
  • Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam, Gyeonggi, 13620, Republic of Korea. sypmd@snu.ac.kr.

Förderung

  • Seoul National University Bundang Hospital
  • Roche Diagnostics Korea
  • Seoul National University

Zitieren

APA

Woo, J. W., Han, E. K., Suh, K. J., Kim, S. H., Kim, J. H., & Park, S. Y. (2024). Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07359-x

Vancouver

Woo JW, Han EK, Suh KJ, Kim SH, Kim JH, Park SY. Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07359-x

BibTeX
@article{Woo2024,
  author = {Woo, Ji Won and Han, Eun Kyung and Suh, Koung Jin and Kim, Se Hyun and Kim, Jee Hyun and Park, So Yeon},
  title = {Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07359-x}
}
Kostenlos starten →